Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Hydrocortisone as effective as triamcinolone for phimosis

06 Oct 2019
Circumcision has been a controversial issue debated in many countries

Over-the-counter hydrocortisone does not perform worse than triamcinolone for grade 4–5 phimosis, a recent study has found.

Researchers randomly assigned boys aged 3–13 years with phimosis to receive either 0.1% triamcinolone (n=19; mean age, 6.6±2.1 years) or 1% hydrocortisone (n=13; mean age, 5.9±2.5 years). Evaluations were performed at weeks 4, 8 and 12, and treatment success was defined as reaching disease grade 2 after 12 weeks of treatment. Only those with grade 3–4 condition at baseline were eligible for inclusion.

In the hydrocortisone group, 30.8 percent (n=4) were successfully treated by week 4. Over the same time span, 31.6 percent (n=6) of the triamcinolone group had been successfully treated. The corresponding rates in either group increased to 53.8 percent and 52.6 percent by week 8 and 61.5 percent and 68.4 percent by week 12.

Between-group differences in success rates failed to reach statistical significance at any time point (week 4: p=0.99; week 8: p=0.99; week 12: p=0.72). The same was true for adherence.

Similarly, patient age (p=0.16) and a prior history of balanitis had no significant effects on the likelihood of treatment success. Having grade 4 or 5 phimosis at baseline was similarly unrelated to the odds of successful treatment (p=0.27).

No adverse events were reported.

The present study shows that topical corticosteroids remain effective for the treatment for phimosis, and that there appears to be no significant relative superiority of one over others. Treatment duration, on the other hand, seems to be a more important factor, such that prolonged topical exposure may lead to greater chances of success, said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 5 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).